phosphorylcholine has been researched along with Cancer of Prostate in 28 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, a panel of normal human prostate cells (HPCs) and tumor cells derived from metastases were studied by (1)H NMR spectroscopy to determine whether the malignant transformation of HPCs results in the elevation of choline compounds." | 3.71 | Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. ( Ackerstaff, E; Bhujwalla, ZM; Nelson, JB; Pflug, BR, 2001) |
| "Bortezomib is a proteasome inhibitor that has shown activity in vitro and in vivo in prostate cancer." | 2.73 | Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. ( Ayala, G; Ding, Y; Frolov, A; Harper, JW; Hayes, TG; Ittmann, MM; Kadmon, D; Li, R; Lynch, RG; MacDonnell, V; Miles, BJ; Mims, MP; Thompson, TC; Tsai, MJ; Wheeler, TM; Yan, J, 2008) |
| "Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation." | 2.73 | The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. ( Cambio, A; Chatta, G; Chee, KG; Evans, CP; Gandara, DR; Lara, PN; Longmate, J; Pan, CX; Pinski, J; Quinn, DI; Twardowski, P, 2007) |
| "Treatment with perifosine was complicated by fatigue and gastrointestinal toxicity." | 2.71 | A phase II study of perifosine in androgen independent prostate cancer. ( Arlen, PM; Chen, C; Chung, EJ; Dahut, WL; Daniels, A; Figg, WD; Gulley, J; Jones, E; Lee, MJ; Parnes, HL; Posadas, EM; Sparreboom, A; Steinberg, SM; Trepel, JB; Trout, A; Wright, J, 2005) |
| "We investigated PC3 prostate cancer, MCF-7 breast cancer and A375 melanoma cells, and determined that, consistent with previous studies, MRS-detectable levels of phosphocholine decreased significantly in all cell lines (to 63%, 50% and 18% of the control, respectively) following MEK inhibition with U0126." | 1.40 | MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition. ( Lodi, A; Ronen, SM; Woods, SM, 2014) |
| "Choline metabolites were resolved by ion-exchange chromatography." | 1.37 | Human prostate cell lines from normal and tumourigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C. ( Maitland, N; Rodrigues, G; Rumsby, M; Schmitt, J; Sharrard, M; Stower, M, 2011) |
| "Human prostate cancer cell line, CWR22RV1, was treated with perifosine, radiation, or CTPR." | 1.37 | The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. ( Brinkman, KL; Butler, EB; Floryk, D; Gao, Y; Huang, Y; Ishiyama, H; Ittmann, M; Mai, W; Sun, M; Teh, BS; Thompson, TC; Wang, X; Xu, B; Zhu, J, 2011) |
| "Perifosine treatment of PC-3 cells resulted in cytostatic and cytotoxic effects." | 1.35 | Perifosine induces differentiation and cell death in prostate cancer cells. ( Floryk, D; Thompson, TC, 2008) |
| "Although prostate cancer in TRAMP mice shares some metabolic features with that in humans, it differs with respect to choline phospholipid metabolism, which could impact upon the interpretation of results from biomarker or chemotherapy/chemoprevention studies." | 1.35 | Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism. ( Edwards, RE; Farmer, PB; Gant, TW; Gescher, AJ; Greaves, P; Jones, DJ; Keun, HC; Steward, WP; Teahan, O; Teichert, F; Verschoyle, RD; Wilson, ID, 2008) |
| "Perifosine is a novel p." | 1.32 | Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. ( Dasmahapatra, GP; Kondapaka, SB; Roy, KK; Sausville, EA; Singh, SS, 2003) |
| "Suramin has shown antitumour activity in vitro and in vivo." | 1.29 | The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994) |
| "Seven patients were diagnosed with prostate cancer, 13 with benign prostatic hypertrophy, and 3 with both conditions." | 1.28 | Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. ( Dalrymple, GV; Finkbeiner, AE; Fowler, AH; Holder, JC; Komoroski, RA; Mullins, MS; Pappas, AA; Sprigg, JR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 14 (50.00) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, MI | 1 |
| Hamid, A | 1 |
| Rath, S | 1 |
| Ateeq, B | 1 |
| Khan, Q | 1 |
| Siddiqui, IA | 1 |
| Adhami, VM | 1 |
| Choudhry, H | 1 |
| Zamzami, MA | 1 |
| Mukhtar, H | 1 |
| Zhang, VY | 1 |
| Westphalen, A | 1 |
| Delos Santos, L | 1 |
| Tabatabai, ZL | 2 |
| Shinohara, K | 2 |
| Vigneron, DB | 1 |
| Kurhanewicz, J | 2 |
| Lodi, A | 1 |
| Woods, SM | 1 |
| Ronen, SM | 1 |
| Wnętrzak, A | 1 |
| Lipiec, E | 1 |
| Łątka, K | 1 |
| Kwiatek, W | 1 |
| Dynarowicz-Łątka, P | 1 |
| Swanson, MG | 1 |
| Keshari, KR | 1 |
| Simko, JP | 1 |
| Carroll, PR | 1 |
| Zektzer, AS | 1 |
| Ayala, G | 1 |
| Yan, J | 1 |
| Li, R | 1 |
| Ding, Y | 1 |
| Thompson, TC | 3 |
| Mims, MP | 1 |
| Hayes, TG | 1 |
| MacDonnell, V | 1 |
| Lynch, RG | 1 |
| Frolov, A | 1 |
| Miles, BJ | 1 |
| Wheeler, TM | 1 |
| Harper, JW | 1 |
| Tsai, MJ | 1 |
| Ittmann, MM | 1 |
| Kadmon, D | 1 |
| Beloueche-Babari, M | 2 |
| Peak, JC | 1 |
| Jackson, LE | 3 |
| Tiet, MY | 1 |
| Leach, MO | 3 |
| Eccles, SA | 1 |
| Al-Saffar, NM | 1 |
| Raynaud, FI | 1 |
| Clarke, PA | 1 |
| Ramírez de Molina, A | 1 |
| Lacal, JC | 1 |
| Workman, P | 2 |
| John-Aryankalayil, M | 1 |
| Palayoor, ST | 1 |
| Cerna, D | 1 |
| Simone, CB | 1 |
| Falduto, MT | 1 |
| Magnuson, SR | 1 |
| Coleman, CN | 1 |
| Rumsby, M | 1 |
| Schmitt, J | 1 |
| Sharrard, M | 1 |
| Rodrigues, G | 1 |
| Stower, M | 1 |
| Maitland, N | 1 |
| Gao, Y | 1 |
| Ishiyama, H | 1 |
| Sun, M | 1 |
| Brinkman, KL | 1 |
| Wang, X | 1 |
| Zhu, J | 1 |
| Mai, W | 1 |
| Huang, Y | 1 |
| Floryk, D | 2 |
| Ittmann, M | 1 |
| Butler, EB | 1 |
| Xu, B | 1 |
| Teh, BS | 1 |
| Arunan, V | 1 |
| Troy, H | 1 |
| te Poele, RH | 1 |
| te Fong, AC | 1 |
| Payne, GS | 1 |
| Griffiths, JR | 1 |
| Judson, IR | 1 |
| Chung, YL | 1 |
| Richman, EL | 1 |
| Kenfield, SA | 1 |
| Stampfer, MJ | 1 |
| Giovannucci, EL | 1 |
| Zeisel, SH | 1 |
| Willett, WC | 1 |
| Chan, JM | 1 |
| Kondapaka, SB | 1 |
| Singh, SS | 1 |
| Dasmahapatra, GP | 2 |
| Sausville, EA | 2 |
| Roy, KK | 2 |
| Didolkar, P | 1 |
| Alley, MC | 1 |
| Ghosh, S | 1 |
| Posadas, EM | 1 |
| Gulley, J | 1 |
| Arlen, PM | 1 |
| Trout, A | 1 |
| Parnes, HL | 1 |
| Wright, J | 1 |
| Lee, MJ | 1 |
| Chung, EJ | 1 |
| Trepel, JB | 1 |
| Sparreboom, A | 1 |
| Chen, C | 1 |
| Jones, E | 1 |
| Steinberg, SM | 1 |
| Daniels, A | 1 |
| Figg, WD | 1 |
| Dahut, WL | 1 |
| Milkevitch, M | 1 |
| Jeitner, TM | 1 |
| Beardsley, NJ | 1 |
| Delikatny, EJ | 1 |
| Vinall, RL | 1 |
| Hwa, K | 1 |
| Ghosh, P | 1 |
| Pan, CX | 2 |
| Lara, PN | 2 |
| de Vere White, RW | 1 |
| Mulders, AC | 1 |
| Nau, S | 1 |
| Li, Y | 1 |
| Michel, MC | 1 |
| Chee, KG | 1 |
| Longmate, J | 1 |
| Quinn, DI | 1 |
| Chatta, G | 1 |
| Pinski, J | 1 |
| Twardowski, P | 1 |
| Cambio, A | 1 |
| Evans, CP | 1 |
| Gandara, DR | 1 |
| Festuccia, C | 1 |
| Gravina, GL | 1 |
| Muzi, P | 1 |
| Millimaggi, D | 1 |
| Dolo, V | 1 |
| Vicentini, C | 1 |
| Bologna, M | 1 |
| Teichert, F | 1 |
| Verschoyle, RD | 1 |
| Greaves, P | 1 |
| Edwards, RE | 1 |
| Teahan, O | 1 |
| Jones, DJ | 1 |
| Wilson, ID | 1 |
| Farmer, PB | 1 |
| Steward, WP | 1 |
| Gant, TW | 1 |
| Gescher, AJ | 1 |
| Keun, HC | 1 |
| Saini, MS | 1 |
| Van Etten, RL | 1 |
| Lopez Lopez, R | 1 |
| van Rijswijk, RE | 1 |
| Wagstaff, J | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Ackerstaff, E | 1 |
| Pflug, BR | 1 |
| Nelson, JB | 1 |
| Bhujwalla, ZM | 1 |
| Helms, SR | 1 |
| Brattain, MG | 1 |
| Pretlow, TG | 1 |
| Kreisberg, JI | 1 |
| Fowler, AH | 1 |
| Pappas, AA | 1 |
| Holder, JC | 1 |
| Finkbeiner, AE | 1 |
| Dalrymple, GV | 1 |
| Mullins, MS | 1 |
| Sprigg, JR | 1 |
| Komoroski, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial Of Oral Perifosine In Patients With Metastatic Androgen Independent Prostate Cancer[NCT00060437] | Phase 2 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas[NCT00644072] | Phase 1 | 33 participants (Actual) | Interventional | 2008-03-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phosphorylcholine and Cancer of Prostate
| Article | Year |
|---|---|
The role of metabolic imaging in radiation therapy of prostate cancer.
Topics: Aged; Biopsy; Creatine; Diagnostic Imaging; Humans; Ki-67 Antigen; Male; Metabolomics; Phosphorylcho | 2014 |
3 trials available for phosphorylcholine and Cancer of Prostate
| Article | Year |
|---|---|
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2008 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Topics: Aged; Androgen Antagonists; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylcholine | 2007 |
24 other studies available for phosphorylcholine and Cancer of Prostate
| Article | Year |
|---|---|
AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.
Topics: Acetylation; Animals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Knockout Techni | 2019 |
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Butadienes; Cell Line, Tumor; Glycolysis; Humans; M | 2014 |
Affinity of alkylphosphocholines to biological membrane of prostate cancer: studies in natural and model systems.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Humans; Male; Models, Biological; | 2014 |
Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.
Topics: Choline; Ethanolamine; Ethanolamines; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Ph | 2008 |
Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells.
Topics: Animals; Biomarkers, Tumor; Cell Line; Cell Movement; Down-Regulation; Gene Expression Regulation, N | 2009 |
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Topics: Adenocarcinoma; Cell Line, Tumor; Choline; Choline Kinase; Down-Regulation; Furans; HCT116 Cells; Hu | 2010 |
Fractionated radiation therapy can induce a molecular profile for therapeutic targeting.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose Fractionation, Radiation; Gene Expressi | 2010 |
Human prostate cell lines from normal and tumourigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C.
Topics: Cell Line, Tumor; Choline; Culture Media; Epithelium; Gene Expression Regulation, Enzymologic; Gene | 2011 |
The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Nude; Phosphoryl | 2011 |
Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Choline Kinase; Colonic Neoplasms; Drug Evaluation, Pr | 2012 |
Choline intake and risk of lethal prostate cancer: incidence and survival.
Topics: Adult; Aged; Betaine; Choline; Cohort Studies; Diet; Disease Progression; Follow-Up Studies; Health | 2012 |
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Topics: Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Activation; | 2003 |
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2004 |
Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells.
Topics: Animals; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Enzyme Activation; Glycerophosphates; H | 2007 |
Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dos | 2007 |
Effects of sphingosine-1-phosphate and sphingosylphosphorylcholine on intracellular Ca2+ and cell death in prostate cancer cell lines.
Topics: Apoptosis; Calcium; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Intracel | 2007 |
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; | 2008 |
Perifosine induces differentiation and cell death in prostate cancer cells.
Topics: Active Transport, Cell Nucleus; Androgens; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Cycle; | 2008 |
Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Choline; Choline Kinase; Disease Models, Animal; Gene Ex | 2008 |
A clinical assay for prostatic acid phosphatase using choline phosphate as a substrate: comparison with thymolphthalein phosphate.
Topics: Acid Phosphatase; Choline; Clinical Enzyme Tests; Colorimetry; Humans; Male; Phenolphthaleins; Phosp | 1981 |
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi | 1994 |
Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.
Topics: Androgens; Cell Line; Cell Transformation, Neoplastic; Choline; Epithelial Cells; Humans; Male; Neop | 2001 |
"Prostatic acid phosphatase?" A comparison of acid phosphatase activities in epithelial cells, granulocytes, monocytes, lymphocytes, and platelets purified by velocity sedimentation in isokinetic gradients of Ficoll in tissue culture medium.
Topics: Acid Phosphatase; Blood Platelets; Copper; Epithelial Cells; Epithelium; Fluorides; Formaldehyde; Gr | 1977 |
Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR.
Topics: Alanine; Citrates; Creatine; Glutamates; Glutamic Acid; Humans; In Vitro Techniques; Magnetic Resona | 1992 |